^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LN-145

    i
    Associations
    News

    Trials

    Company:
    Iovance Biotherap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (NCI-2018-00918) (NCT03449108)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    04/27/2018
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • CD8 • CD28 • CD27
    |
    CD8 expression • CD28 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1
    Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer (IOV-LUN-202) (NCT04614103)
    Phase 2
    Iovance Biotherapeutics, Inc.
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    05/07/2021
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    EGFR • PD-L1 • ALK
    |
    cyclophosphamide • LN-145
    Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer (NCT04111510)
    Phase 2
    Yale University
    Completed
    Last update posted :
    02/23/2024
    Initiation :
    12/23/2019
    Primary completion :
    01/30/2023
    Completion :
    05/11/2023
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • PGR negative
    |
    LN-145